FEATURES OF CELLULAR COMPOSITION OF LYMPHO-MACROPHAGE INFILTRATION IN THE STROMA OF BENIGN AND MALIGNANT NODAL THYROID NEOPLASMS
DOI:
https://doi.org/10.21856/j-PEP.2013.3.02Keywords:
thyroid, nodular goiter, follicular adenoma, cancer, cellular immunityAbstract
It was conducted immunohistochemical definition of the relative amounts of CD8 (T-lymphocytes
suppressor), CD4 (T-lymphocyte helper/inducer), CD3 (total population of T-lymphocytes), CD22
(B-lymphocytes), CD16 (macrophages and natural killer) and interleukin-2-producing cells (IL-2) in
the preparations of euthyroid nodular thyroid disease: single and multinodal colloid goiter, thyroid
follicular adenomas (norm-follicular, macrofollicular, microfollicular, trabecular and solid), thyroid
cancer (follicular, papillary, medullary). The nodular goiter characterized by a low level of T-killer,
IL-2 and CD3 lymphocytes compared with follicular adenoma and thyroid cancer. Follicular adenoma
characterized by a high number of IL-2 and a low ratio T-killer/IL-2. In the samples of thyroid cancer
revealed a high level of lymphocyte with CD3 phenotype and T-killer cells as well as the ratio of
CD4/CD8; CD22, CD4, CD8 were minor, that indicated on the expressed cellular immunosuppression
in thyroid cancer infiltrates.
References
Jarilin AA. Osnovy immunologii, Moskva, 1999:409 p.
Chissov VI, Davydov MI. Onkologija: nacional’noe rukovodstvo, Moskva, 2008:1072 p.
Zemskov AM, Karaulov AV. Klinicheskaja immunologija: uchebnik, Moskva, 2008:432 p.
Haitov RM. Immunologija: uchebnik, Moskva, 2009:320 p.
Bershtejn LM. Onkojendokrinologija: tradicii, sovremennost’ i perspektivy, Sankt-Peterburg, 2004:343 p.
Berezhnaja NM, Chehun VF. Immunologija zlokachestvennogo rosta, Kiev, 2005:792 p.
Harel-Bellan A, Quillet A, Marchiol C, et al. Proc Natl Acad Sci USA 1986; 83(15):5688-5692.
Lanier LL. Ann Rev Immunol 2005; 23:225–274.
Nakajima H, Tomiyama H, Takiguchi M. J Immunol 1995; 155(9): 4139–4142.
Yawata M, Yawata N, ed. Lotze MT, Thomson AW. Natural Killer Cells: Basic Science and Clinical Application, Elsevier, 2009; 6:79-94.
Parham P. Nat Rev Immunol 2005; 5:201-214.
He XX, Chen K, Yang J, et al. Mol Med 2009; 5(1-2):1–10.
Lue H, Kleemann R, Calandra T, et al. Microbes Infect 2002; 4(4):449–60.
Bifulco C, McDaniel K, Leng L, Bucala R. Curr Pharm Des 2008; 14(36):3790–801.
Cantrell DA, Smith KA. Science 1984; 224(4655:1312–6.
Smith KA. Science 1988; 240(4856):1169–76
Finke JH, Rayman PA, Ko JS, et al. Cancer J 2013; 19(4):353-64.
Amadori A, Zamarchi R, De Silvestro G, et al. Nat Med 1995; 1:1279–83. doi: http://doi.org/10.1038/nm1295-1279.
Coughlin CM, Fleming MD, Carroll RG, et al. J Clin Oncol 2006; 24:5725–34.
Page’s F, Galon J, Dieu-Nosjean MC, et al. Oncogene 2010; 29:1093–1102.
Vitale G, Lupoli G, Guarrasi R, et al. J Clin Endocrinol Metabol 2013; 24.
Brosman M. Cs patol 1979; 15(4):215-220.
Liyanage UK, Moore TT, Joo HG, et al. J Immunol 2002; 169:2756–2761.
Ling KL, Pratap SE, Bates GJ, et al. Cancer Immunol 2007; 7:7.
Vikman S, Sommaggio R, De La Torre M, et al. Acta Oncol 2009; 48: 391–400.
Page’s F, Kirilovsky A, Mlecnik B, et al. J Clin Oncol 2009; 35:5944–5951.
Page’s F, Berger A, Camus M, et al. N Engl J Med 2005; 353:2654–2666.
Badoual C, Hans S, Rodriguez J, et al. Clin Cancer Res 2006; 12:465–472.
Coussens LM, Werb Z. Nature 2002; 420:860–867.
Galon J, Costes A, Sanchez-Cabo F, et al. Science 2006; 313:1960–1964.
Niederkorn JY. Curr Opin Immunol 2008; 20:327–331.
Liapi C, Gogali F, Paterakis G, et al. Thyroid 2013; 31.
Yu H, Huang X, Liu X, et al. Endocrine 2013; 44(1):172-81.
ISSN 
ISSN 
